« Previous
Next »
Journal of Hepatology
Volume 49, Issue 3
, Pages 329-338
, September 2008
Prospective analysis of effector and regulatory CD4+ T cells in chronic HCV patients undergoing combination antiviral therapy
To access this article, please choose from the options below
☆ Dr. Terrault receives honoraria and grant support from Roche Pharmaceuticals. No other authors have a potential conflict of interest to report . NIH funded study . This study was funded as a cooperative agreement by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) with co-support from the National Center on Minority Health and Health Disparities (NCMHD) and the Intramural Research Program of the National Cancer Institute (NCI) with further support under a Cooperative Research and Development Agreement (CRADA) with Roche Laboratories, Inc. Grant Nos: U01 DK60329, U01 DK60340, U01 DK 60324, U01 DK 60344, U01 DK60327, U01 DK 60335, U01 DK60352, U01DK 60342, U01 DK 60345, U01 DK 60309, U01 DK 60346, U01 DK 60349, U01 DK 60341. Other support: National Center for Research Resources (NCRR) General Clinical Research Centers Program Grants: M01 RR00645 (New York Presbyterian), M02 RR000079 (University of California, San Francisco), M01 RR 16500 (University of Maryland), M01 RR000042 (University of Michigan), M01 RR00046 (University of North Carolina).
PII: S0168-8278(08)00370-X
doi: 10.1016/j.jhep.2008.05.020
« Previous
Next »
Journal of Hepatology
Volume 49, Issue 3
, Pages 329-338
, September 2008
